Kiniksa Pharmaceuticals International, plc has reported significant share transactions involving its Chief Accounting Officer, Michael R. Megna, according to a recent SEC filing. The transactions, which took place on November 9, 2026, are noteworthy as they reflect ongoing executive activity within the company.
This update is important for Kiniksa Pharmaceuticals, a company focused on pharmaceutical preparations, as it highlights the fluidity of share ownership among its executives. Such movements can influence investor perceptions and market dynamics.
Background
Kiniksa Pharmaceuticals International, plc, with a CIK of 0001730430, operates under the SIC code 2834, which corresponds to Pharmaceutical Preparations. The company trades on the Nasdaq under the ticker symbol KNSA. It is categorized as a large accelerated filer and has been active in the market with several recent filings.
What the Filing Says
The SEC filing reveals that Megna acquired 11,280 shares of Class A Ordinary Shares at a price of $17.76 per share. Additionally, he sold the same number of shares at a weighted average price of $98.54. Following these transactions, he now owns a total of 23,977 shares directly.
Impact
These transactions may affect Kiniksa Pharmaceuticals' investor relations and market perception. The activities of executives, especially in the pharmaceutical sector, can signal confidence or concerns about the company’s future. Investors and analysts will likely scrutinize such movements closely.
What's Next
The filing does not say what happens next.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





